The C-reactive protein-albumin-lymphocyte (CALLY) index represents a novel composite biomarker that integrates three fundamental aspects of cancer pathophysiology: systemic inflammation (CRP), nutritional status (albumin), and immune function (lymphocyte count) [9]. This evidence concerns the gene ALB and cancer.